Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Assets (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Non-Current Assets for 12 consecutive years, with $1.5 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 98.38% year-over-year to $1.5 million; the TTM value through Mar 2026 reached $89.6 million, down 64.97%, while the annual FY2025 figure was $1.6 million, 98.67% down from the prior year.
  • Non-Current Assets hit $1.5 million in Q1 2026 for Syndax Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $121.8 million in Q4 2024 and bottomed at $1.5 million in Q1 2026.
  • Average Non-Current Assets over 5 years is $32.4 million, with a median of $18.3 million recorded in 2023.
  • Year-over-year, Non-Current Assets surged 2707.54% in 2022 and then plummeted 98.67% in 2025.
  • Syndax Pharmaceuticals' Non-Current Assets stood at $7.4 million in 2022, then soared by 329.58% to $32.0 million in 2023, then surged by 280.45% to $121.8 million in 2024, then tumbled by 98.67% to $1.6 million in 2025, then dropped by 8.25% to $1.5 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $1.5 million, $1.6 million, and $22.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.